Last €95.36 EUR
Change Today -0.42 / -0.44%
Volume 3.0
6COP On Other Exchanges
New York
As of 9:00 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

covidien plc (6COP) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/26/15 - €96.60
52 Week Low
02/5/14 - €48.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COVIDIEN PLC (6COP)

covidien plc (6COP) Related Businessweek News

View More BusinessWeek News

covidien plc (6COP) Details

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company operates through Medical Devices and U.S. Medical Supplies segments. It sells advanced surgical solutions comprising stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and ablation products, and interventional lung and gastrointestinal solutions, as well as general surgical solutions, including surgical instruments, sutures, and electrosurgery products; and peripheral vascular therapies, such as compression, dialysis, venous insufficiency, peripheral stents, directional artherectomy, and other products, as well as neurovascular therapies comprising coils, neurovascular stents, flow diversion products, and access and delivery products to support procedures. The company also offers patient monitoring products, such as sensors, monitors, and temperature management products; airway and ventilation products, including airway, ventilator, and inhalation therapy products, as well as breathing systems; and nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products. In addition, it sells patient care products, such as operating room supply products and electrodes; original equipment manufacturer products; and SharpSafety products comprising needles, syringes, and sharps disposal products. The company’s products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. It markets its products through direct sales force and third-party distributors. Covidien plc is based in Dublin, Ireland.

39,500 Employees
Last Reported Date: 11/24/14

covidien plc (6COP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.2M
Senior Vice President and Group President
Total Annual Compensation: $595.3K
Senior Vice President and Group President of ...
Total Annual Compensation: $578.8K
Senior Vice President and General Counsel
Total Annual Compensation: $598.4K
Compensation as of Fiscal Year 2014.

covidien plc (6COP) Key Developments

Covidien plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended December 26, 2014

Covidien plc reported unaudited consolidated earnings results for the first quarter ended December 26, 2014. For the quarter, net sales were $2.686 million against $2.639 million a year ago. Operating income was $0.648 million against $0.531 million a year ago. Income before income taxes was $0.583 million against $0.513 million a year ago. Net income was $0.511 million or $1.12 per diluted share against $0.398 million or $0.87 per diluted share a year ago. Adjusted operating income was $0.664 million against $0.599 million a year ago. Adjusted income before income taxes was $0.611 million against $0.553 million a year ago. Adjusted net income was $0.511 million or $1.11 per diluted share against $0.456 million or $1.00 per diluted share a year ago.

Federal Trade Commission Approves Final Order Preserving Future Competition in the Market for Drug-coated Balloon Catheters Used to Treat Peripheral Artery Disease

The Federal Trade Commission has approved a final order settling charges that Medtronic, Inc.'s $42.9 billion acquisition of Covidien plc would likely be anticompetitive. Under the order, first announced in November 2014, the companies agreed to sell Covidien's drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the complaint, Medtronic and Covidien were developing products to compete with C.R. Bard, Inc., the only U.S. supplier of drug-coated balloon catheters used to treat peripheral artery disease.

Covidien plc to Report Q1, 2015 Results on Jan 22, 2015

Covidien plc announced that they will report Q1, 2015 results at 9:00 AM, GMT Standard Time on Jan 22, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6COP:GR €95.36 EUR -0.42

6COP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $71.43 USD 0.00
Becton Dickinson and Co $143.40 USD 0.00
Boston Scientific Corp $14.84 USD 0.00
Stryker Corp $92.70 USD 0.00
Tyco International Plc $42.39 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation 6COP Industry Range
Price/Earnings 27.8x
Price/Sales 4.6x
Price/Book -- Not Meaningful
Price/Cash Flow 27.7x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at